Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/4/2024 | $32.00 | Mkt Outperform | JMP Securities |
| 9/27/2024 | $19.00 → $23.00 | Buy → Neutral | Citigroup |
| 8/12/2024 | $16.00 | Buy | H.C. Wainwright |
| 5/7/2024 | $7.00 | Buy | Citigroup |
| 3/26/2024 | $8.00 | Buy | Stifel |
Summit Therapeutics Inc. (NASDAQ:SMMT) ("Summit," "we," or the "Company") today announced that Jeff Huber has been appointed to its Board of Directors, effective immediately. "It is an honor to add Jeff Huber to our excellent, diverse group of board members," stated Robert W. Duggan, Chairman and Chief Executive Officer of Summit. "Jeff's executive leadership experience in healthcare and technology and his countless accomplishments evidence his ability to translate what's possible into transformational success. As we seek to change the standard of care for solid tumors based on the potential of ivonescimab, we are thrilled to supplement our outstanding leadership team with a board member
Summit Therapeutics Inc. (NASDAQ:SMMT) ("Summit," "we," or the "Company") today announced that Mostafa Ronaghi, PhD, has been appointed to its Board of Directors, effective immediately. "We are excited to add Dr. Ronaghi to complement our excellent group of current board members," stated Robert W. Duggan, Chairman and Chief Executive Officer of Summit. "Mostafa has valuable experience in translating innovative concepts in genomics and sequencing that ultimately lead to advancements in patient care through his work at Illumina, Grail, and his continuing ventures. As we intend to maximize the potential of ivonescimab, we are excited to add the acumen and expertise that Mostafa can bring to
Joydeep Goswami to serve as advisor through June 30 Illumina reaffirms Q1 2024 and full-year 2024 financial guidance SAN DIEGO, April 9, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced that Joydeep Goswami has decided to leave Illumina. He will stay on in an advisory role through June 30 to support two new executive management team appointments. Ankur Dhingra is joining Illumina as Chief Financial Officer (CFO), leading Illumina's financial planning and analysis, accounting, investor relations,
SC 13D/A - Summit Therapeutics Inc. (0001599298) (Subject)
SC 13D/A - Summit Therapeutics Inc. (0001599298) (Subject)
SC 13D/A - Summit Therapeutics Inc. (0001599298) (Subject)
Summit Therapeutics Inc. (NASDAQ:SMMT) ("Summit," "we," or the "Company") today announced the grant of inducement awards of options to purchase a collective total of up to 227,600 shares of common stock. Awards were made to 15 new employees of the Company. The awards were granted as an inducement material to the new employees becoming employees of the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and have been approved by the Company's Compensation Committee. The inducement awards were granted on November 15, 2024. The options have a ten (10) year term and an exercise price of $18.31 per share, the closing price per share of the Company's common stock as reported by Nasdaq on No
Ivonescimab Monotherapy Became First Drug to Achieve Clinically Meaningful Benefit over Pembrolizumab Monotherapy in a Phase III Randomized Clinical Trial in NSCLC, HARMONi-2, Reducing Risk of Disease Progression or Death by 49% in First-Line PD-L1 Positive Advanced NSCLC in China Enrollment Completed in Global Phase III HARMONi Trial in 2L+ EGFRm Advanced NSCLC; Received Fast Track Designation from FDA; Topline Data Expected in Mid-2025 Summit Intends to Expand HARMONi-3 Global Phase III Trial in 1L Metastatic NSCLC to Include Patients with Tumors of Non-Squamous Histology in Addition to Currently Enrolling Squamous Patients Summit to Initiate Global Phase III HARMONi-7 Trial in 1L PD-L
Nuvectis Pharma (NASDAQ:NVCT) continues to make strides in precision oncology, gaining momentum following presentations last week at the AACR-NCI-EORTC Symposium where its drug candidate NXP900 demonstrated strong synergy with ALK inhibitors in non-small cell lung cancer (NSCLC) cells that despite being driven by ALK fusions, are resistant to treatment with the market leading ALK Inhibitors, alectinib and lorlatinib, showcasing NXP900's potential to address resistance mechanisms in NSCLC. Also, with the growing anticipation of the data update from NXP800 expected soon from the Phase 1b study in platinum resistant, ARID1a-mutated ovarian cancer, Nuvectis is positioning itself at the forefron
JMP Securities initiated coverage of Summit Therapeutics with a rating of Mkt Outperform and set a new price target of $32.00
Citigroup downgraded Summit Therapeutics from Buy to Neutral and set a new price target of $23.00 from $19.00 previously
H.C. Wainwright initiated coverage of Summit Therapeutics with a rating of Buy and set a new price target of $16.00
4 - Summit Therapeutics Inc. (0001599298) (Issuer)
4 - Summit Therapeutics Inc. (0001599298) (Issuer)
4 - Summit Therapeutics Inc. (0001599298) (Issuer)
10-Q - Summit Therapeutics Inc. (0001599298) (Filer)
8-K - Summit Therapeutics Inc. (0001599298) (Filer)
D - Summit Therapeutics Inc. (0001599298) (Filer)
Ivonescimab Monotherapy Became First Drug to Achieve Clinically Meaningful Benefit over Pembrolizumab Monotherapy in a Phase III Randomized Clinical Trial in NSCLC, HARMONi-2, Reducing Risk of Disease Progression or Death by 49% in First-Line PD-L1 Positive Advanced NSCLC in China Enrollment Completed in Global Phase III HARMONi Trial in 2L+ EGFRm Advanced NSCLC; Received Fast Track Designation from FDA; Topline Data Expected in Mid-2025 Summit Intends to Expand HARMONi-3 Global Phase III Trial in 1L Metastatic NSCLC to Include Patients with Tumors of Non-Squamous Histology in Addition to Currently Enrolling Squamous Patients Summit to Initiate Global Phase III HARMONi-7 Trial in 1L PD-L
Conference Call to be Held at 9:00am ET Summit Therapeutics Inc. (NASDAQ:SMMT) ("Summit," "we," or the "Company") will host an earnings call to announce its third quarter 2024 financial results and provide an operational update for the Company on Wednesday, October 30, 2024, before the market opens. Summit will host a live webcast of the earnings conference call at 9:00am ET, which will be accessible through our website, www.smmttx.com. An archived edition of the session will be available on our website. About Ivonescimab Ivonescimab, known as SMT112 in Summit's license territories, the United States, Canada, Europe, Japan, Latin America, including Mexico and all countries in Central Am
Summit to Initiate HARMONi-7, a Phase III Trial in First-Line PD-L1 High, Advanced NSCLC, in Early 2025 Ivonescimab Is the First Drug to Achieve Clinically Meaningful Benefit over Pembrolizumab in a Randomized Phase III Clinical Trial in NSCLC Median PFS of 11.14 Months vs. 5.82 Months, Respectively, for Patients Receiving Ivonescimab vs. Pembrolizumab; PFS Improvement Was Observed Broadly in Patients Across Subgroups, including PD-L1 High and Low Expressing Tumors, Squamous and Non-Squamous Histologies Comparable Serious Treatment-Related Adverse Events and TRAE-Led Discontinuation Rates Were Observed; Serious TRAEs were 20.8% vs. 16.1%, Respectively, in Ivonescimab and Pembrolizumab Ar
4 - Summit Therapeutics Inc. (0001599298) (Issuer)
4 - Summit Therapeutics Inc. (0001599298) (Issuer)
4 - Summit Therapeutics Inc. (0001599298) (Issuer)
U.S. stocks were higher, with the Nasdaq Composite gaining over 100 points on Monday. Shares of IQVIA Holdings Inc. (NYSE:IQV) rose sharply during Monday's session after the company released better-than-expected second-quarter financial results and raised its 2024 guidance. IQVIA reported a second adjusted EPS of $2.64, up from $2.43, beating the consensus of $2.57. Provider of advanced analytics reported sales of $3.81 billion, beating the consensus of $3.79 billion, according to data from Benzinga Pro. IQVIA Holdings shares jumped 7.4% to $241.07 on Monday. Here are some other big stocks recording gains in today’s session. Tellurian Inc. (NASDAQ:TELL) shares surged 64.5% to
These ten mid-cap stocks were the best performers in the last week. Are they in your portfolio? QuantumScape Corporation (NYSE:QS) stock jumped 64.34% after the company announced it entered into an agreement with Volkswagen's battery company PowerCo to industrialize solid-state batteries. Lantheus Holdings, Inc. (NASDAQ:LNTH) shares rocketed 55.93% following a CMS proposal to improve payment for Specialized Diagnostic Radiopharmaceuticals. Sunrun Inc. (NASDAQ:RUN) shares increased 37.59%. as shares of companies within the broader industrial sector gained following recent CPI data. Kymera Therapeutics, Inc. (NASDAQ:KYMR) shares rose 37.38% after the company announced its intentio